NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDIpilimumab Yervoy® Malignant disease and immunosuppression, Ipilimumab, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Ipilimumab Ipilimumab [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA1065: Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA724 Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
NICE TA780 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma